Indraprastha Medical Corporation (INDRAMEDCO) Fair Value & Analysis
Healthcare · IN · Market cap ₹35.7B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated yesterday
Share price −3.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹350.62 – ₹624.80 · fair‑value band ₹262.38 – ₹534.24 · the ₹389.85 price screens below the ₹432.33 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Indraprastha Medical Corporation (INDRAMEDCO) currently trades at ₹389.85, while our model-based Fair Value estimate is ₹432.33 — implying the stock looks roughly 10.9% undervalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Indraprastha Medical Corporation generated revenue of ₹14.8B at a net margin of 12.4%. Revenue grew 9.3% year over year. It earns a return on equity of 27.5%. The balance sheet holds a net cash position of ₹2.3B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Indraprastha Medical Corporation reported revenue of ₹14.8B in FY2026 versus ₹8.9B in FY2022, a compound +13.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +33.0%/yr from FY2022.
Is INDRAMEDCO fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Indraprastha Medical Corporation (INDRAMEDCO) undervalued?
What is the fair value of INDRAMEDCO?
What is the quality score of INDRAMEDCO?
What is the revenue of Indraprastha Medical Corporation (INDRAMEDCO)?
What is the net profit margin of INDRAMEDCO?
Does Indraprastha Medical Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.